Home > Insider Trading > Filing (0001209191-21-054331)

Filing Details

Accession Number:: 0001209191-21-054331
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-01 20:21:27
Reporting Period:: 2021-08-30

Accepted Time:: 2021-09-01 20:21:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563584	M John Leonard	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-08-30	11,637	$13.40	730,942	No	4	M	Direct
Common Stock	Acquisiton	2021-08-30	27,167	$14.58	758,109	No	4	M	Direct
Common Stock	Disposition	2021-08-30	2,055	$152.81	756,054	No	4	S	Direct
Common Stock	Disposition	2021-08-30	2,334	$153.66	753,720	No	4	S	Direct
Common Stock	Disposition	2021-08-30	7,428	$154.98	746,292	No	4	S	Direct
Common Stock	Disposition	2021-08-30	15,567	$155.70	730,725	No	4	S	Direct
Common Stock	Disposition	2021-08-30	4,758	$156.96	725,967	No	4	S	Direct
Common Stock	Disposition	2021-08-30	3,123	$157.75	722,844	No	4	S	Direct
Common Stock	Disposition	2021-08-30	2,598	$159.18	720,246	No	4	S	Direct
Common Stock	Disposition	2021-08-30	725	$159.98	719,521	No	4	S	Direct
Common Stock	Disposition	2021-08-30	216	$160.69	719,305	No	4	S	Direct
Common Stock	Acquisiton	2021-08-31	37,833	$14.58	757,138	No	4	M	Direct
Common Stock	Disposition	2021-08-31	37,833	$155.00	719,305	No	4	S	Direct
Common Stock	Acquisiton	2021-09-01	28,750	$23.46	748,055	No	4	M	Direct
Common Stock	Acquisiton	2021-09-01	15,985	$18.30	764,040	No	4	M	Direct
Common Stock	Disposition	2021-09-01	44,735	$170.00	719,305	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-08-30	11,637	$0.00	11,637	$13.40
Common Stock	Stock Option (right to buy)	Disposition	2021-08-30	27,167	$0.00	27,167	$14.58
Common Stock	Stock Option (right to buy)	Disposition	2021-08-31	37,833	$0.00	37,833	$14.58
Common Stock	Stock Option (right to buy)	Disposition	2021-09-01	28,750	$0.00	28,750	$23.46
Common Stock	Stock Option (right to buy)	Disposition	2021-09-01	15,985	$0.00	15,985	$18.30

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
212,501	2030-03-01	No	4	M	Direct
127,833	2028-12-17	No	4	M	Direct
90,000	2028-12-17	No	4	M	Direct
0	2028-03-20	No	4	M	Direct
11,515	2027-12-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	58,415	Indirect	By Trust

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $153.165, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.22 to $154.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.31 to $155.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $156.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.395 to $158.21, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.49 to $159.465, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.56 to $160.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.62 to $160.745, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 134,583 shares as of August 30, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 160,000 shares as of August 30, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 31, 2020.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,458 shares as of September 1, 2021.